Drug
Vorasidenib clinical trials
Also written AG-881 and VORANIGO.
- studies test it
- 23
- open now
- 7
- in phase 3
- 4
- first study started
- 2015
Keep track of what changes. Save the vorasidenib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
22 studies that test it; most in 2025 (5); 1 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 17
- Phase 2
- 2
- Phase 3
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 11
Institut de Recherches Internationales Servier (6) · Agios Pharmaceuticals, Inc. (5) · Institut de Recherches Internationales Servier (I.R.I.S.) (4) · Servier (Tianjin) Pharmaceutical Co. LTD. (1) · Servier (1) · Servier Bio-Innovation LLC (1) · Megan Mantica (1) · Heidelberg University (1)
Often tested with
Tested in the same studies.
Omeprazole (2) · Temozolomide (1) · Pembrolizumab (1) · Ivosidenib (1) · Bupropion (1) · Flurbiprofen (1) · Midazolam (1) · Repaglinide (1)
Studies
Open first, then newest update. How each study uses vorasidenib is read from its arms, and is right about nine times in ten.
Testing it · 23
- VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 MutationsNot yet recruitingPhase 1Megan ManticaNCT07629089Written as Vorasidenib
- A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)Not yet recruitingPhase 1Heidelberg UniversityNCT07877415Written as Vorasidenib 40 mg Oral Tablet
- Vorasidenib Maintenance for IDH Mutant AstrocytomaRecruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT06809322Written as Vorasidenib
- Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain CancerRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT07215910Written as Vorasidenib
- Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationRecruitingPhase 2Institut de Recherches Internationales Servier (I.R.I.S.)NCT07286292Written as Vorasidenib
- ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade GliomasRecruitingPhase 1Katy Peters, MD, PhDNCT05609994Written as PEPIDH1M vaccine + vorasidenib
- Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control ParticipantsRecruitingPhase 1Institut de Recherches Internationales Servier (I.R.I.S.)NCT07250633Written as Vorasidenib 20mg
- A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)Active, not recruitingNot applicableServier (Tianjin) Pharmaceutical Co. LTD.NCT06969352Written as Vorasidenib
- Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant GliomaActive, not recruitingPhase 1/2Institut de Recherches Internationales ServierNCT06478212Written as Vorasidenib
- Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 MutationActive, not recruitingPhase 3ServierNCT06780930Written as Vorasidenib
- A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female ParticipantsCompletedPhase 1Institut de Recherches Internationales Servier (I.R.I.S.)NCT07235774Written as Vorasidenib
- Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant GliomaActive, not recruitingPhase 1Institut de Recherches Internationales ServierNCT05484622Written as Vorasidenib
- Study of AG-120 and AG-881 in Subjects With Low Grade GliomaCompletedPhase 1Institut de Recherches Internationales ServierNCT03343197Written as AG881
- Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 MutationCompletedPhase 1Institut de Recherches Internationales ServierNCT02481154Written as AG881
- Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult ParticipantsCompletedPhase 1Institut de Recherches Internationales Servier (I.R.I.S.)NCT07235748Written as Vorasidenib
- Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)Active, not recruitingPhase 3Institut de Recherches Internationales ServierNCT04164901Written as Vorasidenib
- A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy SubjectsCompletedPhase 1Servier Bio-Innovation LLCNCT05843708Written as Vorasidenib 40 mg Oral Tablet
- A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic FunctionCompletedPhase 1Institut de Recherches Internationales ServierNCT05674474Written as Vorasidenib
- A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881CompletedPhase 1Agios Pharmaceuticals, Inc.NCT04128787Written as AG881 Formulation 1
- A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian ParticipantsCompletedPhase 1Agios Pharmaceuticals, Inc.NCT04145128Written as AG881
Codes
What other systems call vorasidenib · ClinicalTrials.gg INT001611
- MeSH (NLM) C000716758vorasidenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 789Q85GA8PVORASIDENIBConfirmed FDA, NLM, Wikidata
- Wikidata Q122240747vorasidenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152914VorasidenibOne source FDA
- DrugBank DB17097One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716758 | vorasidenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 789Q85GA8P | VORASIDENIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q122240747 | vorasidenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152914 | Vorasidenib | One source FDA |
| DrugBank | DB17097 | — | One source Wikidata |
Also registered as vorasidenib hemicitric acid hemihydrate (UNII X478M962XG).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.